NASDAQ:KPTI Karyopharm Therapeutics - KPTI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.37 -0.03 (-0.88%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.29▼$3.4850-Day Range$2.48▼$5.2952-Week Range$2.45▼$14.73Volume1.23 million shsAverage Volume3.06 million shsMarket Capitalization$273.48 millionP/E RatioN/ADividend YieldN/APrice Target$9.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Karyopharm Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside177.0% Upside$9.33 Price TargetShort InterestBearish26.70% of Shares Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment0.42Based on 11 Articles This WeekInsider TradingSelling Shares$30,868 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.94) to ($1.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector236th out of 1,027 stocksPharmaceutical Preparations Industry106th out of 500 stocks 3.3 Analyst's Opinion Consensus RatingKaryopharm Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.33, Karyopharm Therapeutics has a forecasted upside of 177.0% from its current price of $3.37.Amount of Analyst CoverageKaryopharm Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted26.70% of the outstanding shares of Karyopharm Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Karyopharm Therapeutics has recently increased by 3.63%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKaryopharm Therapeutics has received a 71.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Other cancer medication", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Karyopharm Therapeutics is -1.11. Previous Next 2.5 News and Social Media Coverage News SentimentKaryopharm Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Karyopharm Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for KPTI on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows4 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,868.00 in company stock.Percentage Held by Insiders10.24% of the stock of Karyopharm Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.13% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($1.94) to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Karyopharm Therapeutics (NASDAQ:KPTI) StockKaryopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.Read More Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KPTI Stock News HeadlinesFebruary 7, 2023 | americanbankingnews.comFY2022 Earnings Estimate for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Issued By Jefferies Financial GroupFebruary 5, 2023 | americanbankingnews.comEquities Analysts Set Expectations for Karyopharm Therapeutics Inc.'s Q1 2023 Earnings (NASDAQ:KPTI)February 7, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. February 2, 2023 | benzinga.comKaryopharm Therapeutics Stock (NASDAQ:KPTI), Quotes and News SummaryJanuary 30, 2023 | americanbankingnews.comKaryopharm Therapeutics (NASDAQ:KPTI) PT Lowered to $5.00January 30, 2023 | americanbankingnews.comAnalysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $9.56January 19, 2023 | benzinga.comBronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Karyopharm Therapeutics Inc. (KPTI) InvestigationJanuary 19, 2023 | msn.comKaryopharm gains as Piper issues bullish remarks citing cancer drugFebruary 7, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. January 15, 2023 | seekingalpha.comKaryopharm Therapeutics (KPTI) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- SlideshowJanuary 9, 2023 | finance.yahoo.comKaryopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 ObjectivesJanuary 4, 2023 | finance.yahoo.comKaryopharm to Present at 41st Annual J.P. Morgan Healthcare ConferenceDecember 28, 2022 | seekingalpha.comKaryopharm: Recent Sell-Off Hits A New Buy TargetDecember 25, 2022 | seekingalpha.comKaryopharm: 6 Months Later, No Change In My StanceDecember 12, 2022 | markets.businessinsider.comKaryopharm Announces Updated Phase 1 Data Of Selinexor Combination In Treatment-Naïve MyelofibrosisDecember 12, 2022 | finance.yahoo.comKaryopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022December 5, 2022 | finance.yahoo.comKaryopharm Announces $165 Million Private PlacementDecember 5, 2022 | finance.yahoo.comKaryopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve MyelofibrosisNovember 21, 2022 | seekingalpha.comMerck deal for Imago is positive for Karyopharm, Prelude – BarclaysNovember 8, 2022 | finance.yahoo.comDoes Karyopharm Therapeutics (KPTI) Have the Potential to Rally 96% as Wall Street Analysts Expect?November 4, 2022 | seekingalpha.comKaryopharm Therapeutics Inc. (KPTI) Q3 2022 Earnings Call TranscriptNovember 3, 2022 | finance.yahoo.comKaryopharm Announces New Selinexor Data in Myelofibrosis and Multiple Myeloma to be Presented at ASH 2022November 1, 2022 | finance.yahoo.comKaryopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of MyelofibrosisOctober 20, 2022 | finance.yahoo.comKaryopharm to Report Third Quarter 2022 Financial Results on November 3, 2022September 23, 2022 | finance.yahoo.comKaryopharm Therapeutics Inc. (KPTI)September 9, 2022 | markets.businessinsider.comExpert Ratings for Karyopharm TherapeuticsSeptember 7, 2022 | finance.yahoo.comKaryopharm to Participate at Upcoming Investor ConferencesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KPTI Company Calendar Last Earnings11/03/2021Today2/06/2023Next Earnings (Estimated)2/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KPTI CUSIPN/A CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees442Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.33 High Stock Price Forecast$16.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+177.0%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,090,000.00 Net Margins-35.26% Pretax Margin-35.19% Return on EquityN/A Return on Assets-32.40% Debt Debt-to-Equity RatioN/A Current Ratio3.61 Quick Ratio3.54 Sales & Book Value Annual Sales$209.82 million Price / Sales1.30 Cash FlowN/A Price / Cash FlowN/A Book Value($1.05) per share Price / Book-3.21Miscellaneous Outstanding Shares81,150,000Free Float72,845,000Market Cap$273.48 million OptionableOptionable Beta-0.04 Key ExecutivesRichard A. PaulsonPresident, CEO & Non-Executive DirectorMike MasonChief Financial Officer, Treasurer & EVPReshma RangwalaChief Medical Officer & Executive Vice PresidentAccumanno JamesChief Compliance OfficerTanya N. LewisChief Regulatory & Quality Officer, Executive VPKey CompetitorsNkartaNASDAQ:NKTXRani TherapeuticsNASDAQ:RANILianBioNASDAQ:LIANInventivaNASDAQ:IVASelecta BiosciencesNASDAQ:SELBView All CompetitorsInsiders & InstitutionsLos Angeles Capital Management LLCBought 23,260 shares on 2/6/2023Ownership: 0.126%Birchview Capital LPBought 22,000 shares on 2/3/2023Ownership: 0.359%Simplex Trading LLCBought 5,100 shares on 2/2/2023Ownership: 0.000%Redwood Wealth Management Group LLCBought 33,230 shares on 2/1/2023Ownership: 0.041%Janney Montgomery Scott LLCBought 10,000 shares on 2/1/2023Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions KPTI Stock - Frequently Asked Questions Should I buy or sell Karyopharm Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KPTI shares. View KPTI analyst ratings or view top-rated stocks. What is Karyopharm Therapeutics' stock price forecast for 2023? 8 brokerages have issued 1-year price objectives for Karyopharm Therapeutics' shares. Their KPTI share price forecasts range from $5.00 to $16.00. On average, they expect the company's stock price to reach $9.33 in the next twelve months. This suggests a possible upside of 177.0% from the stock's current price. View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts. How have KPTI shares performed in 2023? Karyopharm Therapeutics' stock was trading at $3.40 at the start of the year. Since then, KPTI stock has decreased by 0.9% and is now trading at $3.37. View the best growth stocks for 2023 here. When is Karyopharm Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023. View our KPTI earnings forecast. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by $0.01. The company had revenue of $37.69 million for the quarter, compared to the consensus estimate of $25.84 million. During the same quarter last year, the firm earned ($0.73) earnings per share. What guidance has Karyopharm Therapeutics issued on next quarter's earnings? Karyopharm Therapeutics updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $157.70 million-$157.70 million, compared to the consensus revenue estimate of $161.68 million. What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO? 31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY). What is Karyopharm Therapeutics' stock symbol? Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI." Who are Karyopharm Therapeutics' major shareholders? Karyopharm Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Birchview Capital LP (0.36%), Hennion & Walsh Asset Management Inc. (0.18%), Los Angeles Capital Management LLC (0.13%), New York State Common Retirement Fund (0.06%), Redwood Wealth Management Group LLC (0.04%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include Christopher Brett Primiano, Deepika Pakianathan, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Michael Mason, Ran Frenkel, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Tanya Lewis. View institutional ownership trends. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Karyopharm Therapeutics' stock price today? One share of KPTI stock can currently be purchased for approximately $3.37. How much money does Karyopharm Therapeutics make? Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $273.48 million and generates $209.82 million in revenue each year. The company earns $-124,090,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. How many employees does Karyopharm Therapeutics have? The company employs 442 workers across the globe. How can I contact Karyopharm Therapeutics? Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for the company is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at ikarp@karyopharm.com. This page (NASDAQ:KPTI) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.